Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of fingolimod combined with SSRI or SNRI antidepressant therapy in relapsing-remitting multiple sclerosis with mild to moderate depression
2011-001692-39Phase 4Terminated
- Sponsor
- Novartis
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of fingolimod, fluoxetine and venlafaxine in multiple sclerosis (MS) and major depressive disorder (MDD) (2 arms), sponsored by Novartis. Started Jun 2011; status: terminated.
02
Drugs
fingolimodfluoxetinevenlafaxine
03
Conditions
multiple sclerosis (MS)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2011-001692-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001692-39.